Results 201 to 210 of about 72,872 (321)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Obstacle-avoidance trajectory planning method for excavators in confined spaces based on improved RRT* algorithm. [PDF]

Sci Rep
Fu S, Lin C, Yao Z, Lin T, Chen Q.
europepmc   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Movement smoothness matters: The missing piece in the functional assessment of rotator cuff patients. Insights from a stereophotogrammetry experimental study. [PDF]

J Exp Orthop
Mancini L, De Sanctis L, Schena E, D'Hooghe P, de Sire A, Mancuso M, Nazarian A, Carnevale A, Longo UG.   +8 more
europepmc   +1 more source

Accelerator driven systems. Subcritical level monitoring: evaluation of spatial correction factors for source-jerk and area methods

, 2006
F. Gabrielli, M. Carta, A. D’Angelo
openalex   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Spatiotemporal kinematic parameters reflect spasticity level during forward reaching in children with hemiplegic cerebral palsy: correlation and regression analysis. [PDF]

Sci Rep
Hegazy F, Hassan A, Mohamed Kamel S, Al-Sharman A, Bairapareddy K, Arumugam A, Al Abdi R, Salem Y, Aboelnasr E.   +8 more
europepmc   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Extraction of driving behavior primitives considering driver expectation and vehicle dynamics. [PDF]

PLoS One
Ren Y, Cui X, Zheng X, Li X, Xi J.
europepmc   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source